Medincell (XPAR:MEDCL) Asset Impairment Charge : €0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Medincell Asset Impairment Charge?

Medincell's Asset Impairment Charge for the six months ended in Sep. 2023 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

Medincell Asset Impairment Charge Historical Data

The historical data trend for Medincell's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Asset Impairment Charge Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Asset Impairment Charge

Get a 7-Day Free Trial

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Asset Impairment Charge	Get a 7-Day Free Trial										-	-	-	-	-

Medincell Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Medincell Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Medincell's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (XPAR:MEDCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines